Literature DB >> 20394070

Inhibition of HSV-1 attachment, entry, and cell-to-cell spread by functionalized multivalent gold nanoparticles.

Dana Baram-Pinto1, Sourabh Shukla, Aharon Gedanken, Ronit Sarid.   

Abstract

The use of modified nanoparticles in interactions with biological targets is attracting rapidly increasing attention. In this Full Paper, the application of gold nanoparticles capped with mercaptoethanesulfonate (Au-MES NPs) as effective inhibitors of Herpes simplex virus type 1 infection based on their ability to mimic cell-surface-receptor heparan sulfate is described. Mechanistic studies reveal that Au-MES NPs interfere with viral attachment, entry, and cell-to-cell spread, thereby preventing subsequent viral infection in a multimodal manner. The ligand multiplicity achieved with carrier nanoparticles is crucial in generating polyvalent interactions with the virus at high specificity, strength, and efficiency. Such multivalent-nanoparticle-mediated inhibition is a promising approach for alternative antiviral therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20394070     DOI: 10.1002/smll.200902384

Source DB:  PubMed          Journal:  Small        ISSN: 1613-6810            Impact factor:   13.281


  41 in total

1.  Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism.

Authors:  Valeria Cagno; Patrizia Andreozzi; Marco D'Alicarnasso; Paulo Jacob Silva; Marie Mueller; Marie Galloux; Ronan Le Goffic; Samuel T Jones; Marta Vallino; Jan Hodek; Jan Weber; Soumyo Sen; Emma-Rose Janeček; Ahmet Bekdemir; Barbara Sanavio; Chiara Martinelli; Manuela Donalisio; Marie-Anne Rameix Welti; Jean-Francois Eleouet; Yanxiao Han; Laurent Kaiser; Lela Vukovic; Caroline Tapparel; Petr Král; Silke Krol; David Lembo; Francesco Stellacci
Journal:  Nat Mater       Date:  2017-12-18       Impact factor: 43.841

2.  Gold nanoprobes for theranostics.

Authors:  Balaji Panchapakesan; Brittany Book-Newell; Palaniappan Sethu; Madhusudhana Rao; Joseph Irudayaraj
Journal:  Nanomedicine (Lond)       Date:  2011-12       Impact factor: 5.307

3.  Virostatic potential of micro-nano filopodia-like ZnO structures against herpes simplex virus-1.

Authors:  Yogendra Kumar Mishra; Rainer Adelung; Claudia Röhl; Deepak Shukla; Frank Spors; Vaibhav Tiwari
Journal:  Antiviral Res       Date:  2011-08-26       Impact factor: 5.970

Review 4.  Role of metal and metal oxide nanoparticles as diagnostic and therapeutic tools for highly prevalent viral infections.

Authors:  Tejabhiram Yadavalli; Deepak Shukla
Journal:  Nanomedicine       Date:  2016-08-26       Impact factor: 5.307

5.  Prophylactic, therapeutic and neutralizing effects of zinc oxide tetrapod structures against herpes simplex virus type-2 infection.

Authors:  Thessicar E Antoine; Yogendra K Mishra; James Trigilio; Vaibhav Tiwari; Rainer Adelung; Deepak Shukla
Journal:  Antiviral Res       Date:  2012-10-06       Impact factor: 5.970

6.  Antiviral Activity of Zinc Oxide Nanoparticles Mediated by Plumbago indica L. Extract Against Herpes Simplex Virus Type 1 (HSV-1).

Authors:  Mina Michael Melk; Seham S El-Hawary; Farouk Rasmy Melek; Dalia Osama Saleh; Omar M Ali; Mohamed A El Raey; Nabil Mohamed Selim
Journal:  Int J Nanomedicine       Date:  2021-12-18

7.  Elucidating Design Principles for Engineering Cell-Derived Vesicles to Inhibit SARS-CoV-2 Infection.

Authors:  Taylor F Gunnels; Devin M Stranford; Roxana E Mitrut; Neha P Kamat; Joshua N Leonard
Journal:  Small       Date:  2022-04-07       Impact factor: 15.153

Review 8.  Use of nanotechnology in combating coronavirus.

Authors:  Saee Gharpure; Balaprasad Ankamwar
Journal:  3 Biotech       Date:  2021-06-28       Impact factor: 2.406

9.  Ecotoxicity of nanoparticles.

Authors:  Sachindri Rana; P T Kalaichelvan
Journal:  ISRN Toxicol       Date:  2013-03-24

10.  Tin oxide nanowires suppress herpes simplex virus-1 entry and cell-to-cell membrane fusion.

Authors:  James Trigilio; Thessicar E Antoine; Ingo Paulowicz; Yogendra K Mishra; Rainer Adelung; Deepak Shukla
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.